Snapshot
When sponsors and CROs evaluate clinical trial technology, the platform usually gets top billing: its capabilities, integrations, and configurability. That's the right instinct—technology matters. But after years in this space, I've come to believe the real determinant of whether a trial runs well isn't just the software. It's who's operating alongside you throughout the life of that study.
I've worked in clinical trial technology for a long time, across several companies and product sets, and the pattern holds. The customers who feel well supported get more than fast ticket resolution. They're working with a team that understands what they're trying to accomplish operationally—one that knows enough to push back, offer alternatives, and surface problems early. That's what I mean by operational expertise—a specific kind of knowledge, distinct from knowing the software.
Technology expertise and operational expertise are not the same thing. Knowing our platform thoroughly is table stakes for a vendor. The harder question is whether they understand the clinical operations the customer is trying to execute.
Here's an example. A customer running site payments in multiple countries tells us they need to pay sites in Bulgaria. What they may not appreciate is how specific that gets. A single visit can require splitting payment across the clinic, the physician, and the hospital, each with its own requirements. We've done this in the region before, so we know which questions to ask. Importantly, we ask them while the spec is still being written, before UAT surfaces the gap. That's proactive consultation, with domain knowledge applied early enough to change the outcome.
The same dynamic plays out elsewhere. On the RTSM side, customers who aren't working in randomization and trial supply every day may not know what a reasonable drug holdback threshold looks like for a given country, or where a routine-seeming protocol choice creates a downstream supply problem. We do, and we raise it early.
Suvoda built its reputation in RTSM through years of consistent, disciplined execution. My goal is to hold that same standard across every product as we bring Suvoda and Greenphire together.
Concretely, that means treating consultation as a core service rather than an add-on. It means thinking through the protocol decisions that look low-risk on paper but can cause trouble in execution and offering scenarios and best practices when a customer already has a direction in mind. And it means bringing regional expertise to the table: country-specific site and payment requirements, culturally appropriate travel logistics, eCOA translation and localization, and drug supply nuances that vary by geography.
We describe our technology as purpose-built for clinical trials and flexible enough to meet exact requirements. The same expectation applies to our people. Our teams seek to understand your goals, your priorities, and the way you work, so the service is as fit to your trial as the technology is.
Every vendor claims their people are the experts. What backs the claim is the tenure and trajectory of the team itself.
When a project manager or design consultant has spent six to ten years running studies in a therapeutic area and done that work here, they carry something you can't staff quickly.
They know where studies tend to break. They remember the one with the unusual edge case and bring that expertise to yours. A lot of our managers and team leads came up through the organization. They started as associate project managers, built studies, and were on the calls when things went sideways. That continuity matters because it means our leadership understands the work at the trial level.
Agentic AI is changing what's operationally feasible for a services organization. For a long time, configuring a clinical trial system has followed one model: fill out a detailed specification, hand it over, and wait. The spec has to be exhaustive, because whatever it misses surfaces at UAT, and fixing it then is slow. Agentic AI enables something closer to a working session. We build quickly, show the customer the system as it takes shape, and refine it against what they actually see—arriving at a version that reflects what they need, not only what they managed to put in a document.
That frees the team for the work that needs human judgment such as weighing the protocol decisions that carry risk, asking the questions a customer hasn't thought to ask, and providing guidance no AI model will replace.
For sponsors and CROs, the result is less time managing a specification and more time applying your own clinical and operational judgment where it counts.
Discussions of which vendors stand out in this industry tend to fixate on the technology. But sponsors and CROs who've lived through a hard trial rarely remember the software first. They remember whether the people supporting them knew what they were doing, and whether those people were ahead of the problems or chasing them.
We take that seriously, and as we continue to bring the combined organization together, holding that standard across every product is the work in front of us. Suvoda's technology is built for clinical trials. The people behind it must be too.
David Geismar
SVP, Global Client
Delivery, Suvoda
ON-DEMAND WEBINAR